NCT00054132View on ClinicalTrials.gov

Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

38

Participants

Timeline

Start Date

December 31, 2002

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions
Recurrent Breast CarcinomaStage IV Breast Cancer
Interventions
BIOLOGICAL

Bevacizumab

Given IV

DRUG

Erlotinib Hydrochloride

Given PO

OTHER

Laboratory Biomarker Analysis

Correlative studies

Trial Locations (2)

10065

Memorial Sloan-Kettering Cancer Center, New York

94115

UCSF Medical Center-Mount Zion, San Francisco

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH

NCT00054132 - Erlotinib Hydrochloride and Bevacizumab in Treating Patients With Stage IV Breast Cancer | Biotech Hunter | Biotech Hunter